EULAR 2018 Review
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
• Ogdie A, de Vlam K, McInnes IB, Mease PJ, Baer P, Lukic T, Kwok K, Wang C, Hsu M-A, Maniccia A. Effect of<br />
tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.<br />
Abstract 0221.<br />
• Pohlmeyer C, Cui Z-H, Han P, Clarke AS, Jones RM, Mollova N, Mikaelian I, Zaboli S, Shauf A, Di Paolo JA.<br />
Monotherapy with filgotinib, a JAK1-selective inhibitor, reduces disease severity and alters immune cell subsets<br />
in the NZB/W F1 murine model of Lupus. Abstract 0484.<br />
• Pope J, Michaud K, Emery P, Zhu B, Gaich C, DeLozier A, Zhang X, Dickson C, Smolen JS. Reduction in<br />
fatigue and pain are associated with improved work productivity in patients with RA. Abstract 0240.<br />
• Ritchlin C, Giles J, Ogdie A, Gomez-Reino J, Stockert L, Young P, Wang C, Romero AB, Kudlacz E. Tofacitinib<br />
in patients with psoriatic arthritis and metabolic syndrome: a post-hoc analysis of Phase 3 studies. Abstract<br />
0317.<br />
• Smolen JS, Cohen S, Emery P, Rigby W, Tanaka Y, Zhang Y, Friedman A, Othman AA, Camp HS, Pangan AL.<br />
Upadacitinib as monotherapy: a Phase 3 randomized controlled double-blind study in patients with active<br />
rheumatoid arthritis and inadequate response to methotrexate. Abstract 0035.<br />
• Soriano ER, Madariaga H, Castañeda O, Citera G, Schneeberger EE, Cardiel MH, Hendrikx T, Graham D, Shi<br />
H, Ponce de Leon D. Liver enzyme abnormalities after tofacitinib treatment in patients with hepatic steatosis<br />
from the rheumatoid arthritis, psoriatic arthritis and psoriasis clinical programmes. Abstract 0099.<br />
• Strand V, Mysler E, Moots RJ, Wallenstein G, DeMasi R, Gruben D, Soma K, Iikuni N, Fleischmann R.<br />
Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid<br />
arthritis: patient-reported outcomes from a Phase 3B/4 randomised trial. Abstract 0256.<br />
• Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff<br />
M. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate<br />
response to conventional synthetic disease-modifying anti-rheumatic drugs: results from select-next. Abstract<br />
0254.<br />
• Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J.<br />
Patient reported outcomes of upadacitinib: results from biologic inadequate responders (SELECT BEYOND<br />
Phase III trial). Abstract 0255.<br />
• Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Correia AP, Otawa S, Lopez-Romero P, de La Torre<br />
I, Rooney T, Smolen JS. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained<br />
disease control: results of a prospective study. Abstract 0253.<br />
• Takeuchi T, Smolen JS, Fleischmann R, Iikuni N, Fan H, Soma K, Akylbekova E, Hirose T. Clinical and<br />
functional response to tofacitinib and adalimumab in patients with rheumatoid arthritis: probability plot analysis<br />
of results from the ORAL strategy trial. Abstract 0252.<br />
• Tamura N, Kuwana M, Atsumi T, Takei S, Harigai M, Fujii T, Matsuno H, Mimori T, Momohara S, Yamamoto K,<br />
Nomura K, Endo Y, Sugiyama N, Hirose T, Morishima Y, Yoshii N, Takagi M. Post-marketing surveillance of<br />
tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data. Abstract 0495.<br />
• Tanaka Y, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, Othman AA, Pangan AL, Kitamura S,<br />
Matsuda N, Meerwein S, Kameda H. A Phase 2B/3 randomized, placebo-controlled, double-blind study of<br />
upadacitinib, a selective JAK1 inhibitor, in Japanese patients with active rheumatoid arthritis and inadequate<br />
response to conventional synthetic DMARDS. Abstract 0257.<br />
• van Vollenhoven R, Dore R, Chen K, Camp HS, Enejosa J, Shaw T, Suboticki JL, Hall S. Impact of 12 weeks of<br />
upadacitinib treatment on individual and composite disease measures in patients with rheumatoid arthritis and<br />
inadequate response to conventional synthetic or biologic DMARDS. Abstract 0244.<br />
• Vieira-Sousa E, Eusébio M, Ávila-Ribeiro P, Khmelinskii N, Machado AR, Rocha TM, Bernardes M, Santos-<br />
Faria D, Silva JL, Santos H, Miguel C, Carvalho P, Costa T, Teixeira L, Meirinhos T, Nero P, Santos MJ. Tumor<br />
necrosis factor inhibitors persistence in psoriatic arthritis patients. Abstract 0920.<br />
• Wiesenhutter C. Initiating tofacitinib in a treat to target strategy for rheumatoid arthritis leads to blunted multibiomarker<br />
disease activity scores as compared to anti-tumour necrosis factor agents. Abstract 0089.<br />
• Youssef P, Marcal B, Button P, Truman M, Bird P, Griffiths H, Roberts L, Tymms K, Littlejohn G. Reasons for<br />
bDMARD cessation and subsequent persistence of second line treatment in a large real world rheumatoid<br />
arthritis registry. Abstract 0165.<br />
• Yu CK-L. Clinical and musculoskeletal ultrasound assessment of therapeutic response to tofacitinib in patients<br />
with rheumatoid arthritis: real-world clinical experience from a single center in Hong Kong. Abstract 0210.<br />
• Zengin B, Inanç N, Akar S, Can G, Dalkilic E, Tufan A, Senel S, Koca SS, Capar S, Tugsal HY, Birlik M, Akkoc<br />
N, Onen F. Similar efficacy of tofacitinib on disease activity in rheumatoid arthritis patients with and without<br />
previous biologicals; results from the TURKBIO registry. Abstract 0482.